medigraphic.com
Boletín Médico del Hospital Infantil de México

2012, Number 3

<< Back Next >>

Bol Med Hosp Infant Mex 2012; 69 (3)

Comparison, in relation to outcome, of the clinical characteristics at diagnosis of children with acute lymphoblastic leukemia affiliated with the Seguro Popular insurance program

Dorantes-Acosta E, Zapata-Tarrés M, Miranda-Lora A, Medina-Sansón A, Reyes-López A, Peña CH, Cortés-Gallo G, Muñoz-Hernández O, Garduño-Espinosa J

Language: Spanish
References: 30
Page: 190-196
PDF size: 401.82 Kb.


ABSTRACT

Background. Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood. Patients are classified according to clinical, biological, and molecular characteristics as well as their response to initial therapy. The objective of this study is aimed to characterize the diagnostic findings in a sample of Mexican patients with ALL and to identify clinical differences according to crude mortality.
Methods. We reviewed clinical records of 391 pediatric ALL patients in nine hospitals in Mexico affiliated with the Seguro Popular insurance program.
Results. Included in this study were 296 living patients and 95 deceased patients. Mean age was 6.48 years and 8.31 years for living and deceased patients, respectively. Signs and symptoms associated with seeking medical care were fever, pallor, fatigue and weakness. The main hematologic abnormalities were anemia and thrombocytopenia. The largest proportion of blasts in peripheral blood was observed in the group of deceased patients; 86.4% of the sample had immunophenotype in the clinical record and only 11.2% had cytogenetic study. One hundred forty eight patients were classified as standard risk and 230 patients as high risk.
Conclusions. To characterize the population of children with ALL allows health systems to be aware of the features of patients with ALL and to implement specific actions and to develop strategies so that all patients have access to immunophenotype and cytogenetic studies.


REFERENCES

  1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. Cancer statistics review 1975-2008. National Cancer Institute. Online Surveillance Epidemiology and End Results. Disponible en: http://seer.cancer.gov/csr/1975_2008/#contents

  2. Ries LA, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. National Cancer Institute. Online Surveillance Epidemiology and End Results. Disponible en: http://seer.cancer.gov/publications/childhood/.

  3. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003;97:2229-2235.

  4. McNeil DE, Coté TR, Clegg L, Mauer A. SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol 2002;39:554-557.

  5. Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 1994;70:996-972.

  6. Woods WG, Roloff JS, Lukens JN, Krivit W. The occurrence of leukemia in patients with the Shwachman syndrome. J Pediatr 1981;99:425-428.

  7. Passarge E. Bloom’s syndrome: the German experience. Ann Genet 1991;34:179-197.

  8. Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996;87:423-438.

  9. Whitlock JA. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 2006;135:595-602.

  10. Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon PS, et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer 2005;44:21-28.

  11. Whitlock JA, Sather HN, Gaynon P, Robinson LL, Wells RJ, Trigg M, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 2005;106:4043-4049.

  12. Pérez-Zaldívar ML, Fajardo-Gutiérrez A, Bernáldez-Ríos R, Martínez-Ávalos A, Medina-Sansón A, Espinosa-Hernández L, et al. Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology. BMC Cancer 2011;11:355-366.

  13. Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA 2003;290:2008-2014.

  14. Tefferi A, Killmann NM. Globalization of treatment strategies in leukemia: challenges and responsibilities. Leukemia 2008;22:1093-1094.

  15. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol 1981;4:553-561.

  16. Shuster JJ, Wacker P, Pullen J, Humbert J, Land VJ, Mahoney DH Jr, et al. Prognostic significance of sex in childhood Bprecursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 1998;16:2854-2863.

  17. Raimondi SC, Pui CH, Hancock ML, Behm FG, Filatov L, Rivera GK. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia 1996;10:213-224.

  18. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996;88:4252-4258.

  19. Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group. Blood 1997;90:571-577.

  20. Pui CH, Frankel LS, Carroll AJ, Raimondi SC, Shuster JJ, Head DR, et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood 1991;77:440-447.

  21. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-1548.

  22. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood 2004;104:2690-2696.

  23. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29:551-565.

  24. Margolin JF, Rabin KR, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. En: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincot Williams & Williams; 2011. pp. 518-565.

  25. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178.

  26. Pui CH, Boyett JM, Relling MV, Harrison PL, Rivera GK, Behm FG, et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 1999;17:818-824.

  27. Schafer ES, Hunger SP. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol 2011;8:417-424.doi:10.1038/nrclinonc.2011.77

  28. Ribera JM, Oriol A. Acute lymphoblastic leukemia in adolescents and young adults. Hematol Oncol Clin North Am 2009;23:1033-1042.

  29. Pieters R, Carroll WL. Biology and treatment of acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2010;24:1-18.

  30. Nemecek ER, Matthews DC. Antibody-based therapy of human leukemia. Curr Opin Hematol 2002;9:316-321.




2020     |     www.medigraphic.com